

FIG. 1




FIG. 2



Replacement Sheet




FIG. 3




FIG. 4




FIG. 5




FIG. 6

FEB 09 2004




FIG. 7




FIG. 8




FIG. 9



STUDY 002
RETROSPLEINAL CORTICAL ASTROCYTOSIS




FIG. 10A




FIG. 10B



Replacement Sheet

STUDY 006
THERAPEUTIC EFFICACY OF A β FRAGMENTS
TOTAL A β CORTICAL DATA




FIG. 11

STUDY 006
CORTICAL AMYLOID BURDEN




FIG. 12



STUDY 006
AB1-42-BINDING ANTIBODY TITERS




FIG.13

ANTIBODY RESPONSES TO AN 1792 WITH DIFFERENT ADJUVANTS




FIG.14




FIG. 16



Mean Titer of Mice Treated with Monoclonal Anti-Abeta Antibody




FIG. 17



Mean Titer of Mice Treated with Monoclonal
21F12 Anti-Abeta Antibody




FIG. 18



**Group 9: F10920M, 300 μ g AN1792 + 100 μ g QS21
Dosing Schedule 2 titer = 84,484 (normalized to 8)**





FIG. 19



Group 11: F10975F, 300 μ g AN1792 + 100 μ g QS21
Dosing Schedule 3 Titer = 38,632 (normalized to 8)



Peptide ID
FIG. 20